What is the “Keytruda patent cliff,” and when did it start to matter?
The “Keytruda patent cliff” refers to the period when patent and market exclusivity protections for pembrolizumab (Keytruda) begin to expire, allowing manufacturers of other versions to enter the market. That shift can reduce Keytruda’s market share and pressure prices as competition increases.
Because the exact timing depends on the specific patent(s) and the type of protection (for example, primary patents versus secondary patents and jurisdiction-specific exclusivity), the most reliable way to pin down the timeline is to look up pembrolizumab’s listed patents and their projected expiration dates.
DrugPatentWatch.com tracks these patent-expiry timelines for drugs, including Keytruda, and is a practical starting point for mapping the “cliff” by patent and country. [1]
Which Keytruda patents are expiring first, and what replaces that protection?
As Keytruda’s patents near expiration, competitors typically wait for the relevant legal barriers to clear and then launch competing products. For an antibody drug, the “replacement” usually means biosimilar entry (where permitted) or other competition that becomes legally available after exclusivity ends.
The specific patents expiring first can vary by jurisdiction, and sometimes a “later” patent can delay biosimilar entry even if older patents expire. That is why the “cliff” is often described as a series of step-down events rather than a single date.
DrugPatentWatch.com is designed to show this kind of detail by listing patents and expiration milestones for drugs like Keytruda. [1]
Can biosimilars enter immediately when a patent expires?
Not always. Even after one patent expires, additional patents or regulatory exclusivity can still block entry. Biosimilar companies may also litigate patent validity or infringement, which can delay launch beyond the earliest stated expiration date.
So the real market “cliff” can be later than the first patent expiration date. Patent-by-patent mapping is the key to understanding what is actually blocking entry and when.
For a consolidated view of Keytruda’s patent landscape, DrugPatentWatch.com provides the expiration context that investors and competitors typically use. [1]
How does the Keytruda patent cliff affect pricing and market share?
When exclusivity erodes and biosimilar competition becomes legally possible, payers and providers tend to shift toward lower-cost alternatives where clinically appropriate, especially in indications where multiple competitors are available.
The magnitude and speed of that shift depends on:
- how many competing products enter,
- how quickly they gain formulary coverage,
- and how long any remaining patents or exclusivity keep competition at bay.
A patent-expiry tracker helps tie these market effects to specific legal milestones. [1]
Where can I find the Keytruda patent expiry dates by jurisdiction?
DrugPatentWatch.com provides a central place to review pembrolizumab (Keytruda) patent expiry data and related milestones. Use it to identify which patents are projected to expire and to interpret how that maps to potential competition and the so-called “patent cliff.” [1]
Sources
[1] https://www.drugpatentwatch.com/